Diplomat Pharmacy (DPLO) Getting Somewhat Favorable News Coverage, Study Shows
Media headlines about Diplomat Pharmacy (NYSE:DPLO) have trended somewhat positive this week, according to Accern Sentiment. Accern scores the sentiment of media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Diplomat Pharmacy earned a daily sentiment score of 0.16 on Accern’s scale. Accern also gave news articles about the company an impact score of 45.6660085550174 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
These are some of the news articles that may have effected Accern’s analysis:
- Diplomat Pharmacy Shows Rising Price Performance With Jump To 92 RS Rating (finance.yahoo.com)
- Diplomat Selected to Dispense CALQUENCE® for Previously-Treated Mantle Cell … (prnewswire.com)
- Diplomat Selected to Dispense CALQUENCE® for Previously-Treated Mantle Cell Lymphoma (finance.yahoo.com)
- HCA Holdings (HCA) and Diplomat Pharmacy (DPLO) Financial Analysis (americanbankingnews.com)
- Diplomat Pharmacy : Names Executive Vice President of Sales, Payor Strategies – (4-traders.com)
Shares of Diplomat Pharmacy (NYSE DPLO) traded up $0.08 during midday trading on Friday, reaching $20.84. The company’s stock had a trading volume of 336,885 shares, compared to its average volume of 379,961. The company has a market capitalization of $1.39 billion, a P/E ratio of 27.93, a PEG ratio of 4.12 and a beta of 0.74. The company has a quick ratio of 0.88, a current ratio of 1.40 and a debt-to-equity ratio of 0.19.
Diplomat Pharmacy (NYSE:DPLO) last released its quarterly earnings results on Monday, August 7th. The company reported $0.25 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.15 by $0.10. The company had revenue of $1.13 billion for the quarter, compared to analysts’ expectations of $1.14 billion. Diplomat Pharmacy had a return on equity of 7.97% and a net margin of 0.27%. The business’s quarterly revenue was up 3.5% compared to the same quarter last year. During the same period in the previous year, the business posted $0.23 earnings per share. research analysts expect that Diplomat Pharmacy will post 0.75 EPS for the current fiscal year.
DPLO has been the topic of a number of research analyst reports. Zacks Investment Research downgraded Diplomat Pharmacy from a “hold” rating to a “sell” rating in a research report on Monday, July 17th. Needham & Company LLC initiated coverage on Diplomat Pharmacy in a research report on Friday, July 21st. They issued a “buy” rating and a $19.75 target price on the stock. BidaskClub downgraded Diplomat Pharmacy from a “hold” rating to a “sell” rating in a research report on Monday, July 31st. TheStreet upgraded Diplomat Pharmacy from a “d+” rating to a “c-” rating in a research report on Thursday, August 10th. Finally, Robert W. Baird reiterated a “buy” rating and issued a $20.00 target price on shares of Diplomat Pharmacy in a research report on Sunday, September 17th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. Diplomat Pharmacy presently has an average rating of “Buy” and an average price target of $19.36.
ILLEGAL ACTIVITY NOTICE: “Diplomat Pharmacy (DPLO) Getting Somewhat Favorable News Coverage, Study Shows” was first published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright and trademark law. The original version of this piece of content can be viewed at https://www.watchlistnews.com/diplomat-pharmacy-dplo-getting-somewhat-favorable-news-coverage-study-shows/1678882.html.
Diplomat Pharmacy Company Profile
Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.
Receive News & Ratings for Diplomat Pharmacy Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.